{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:48:05Z","timestamp":1756572485180},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00393-022-01293-3","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T13:03:14Z","timestamp":1671022994000},"page":"134-142","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adultes Still-Syndrom"],"prefix":"10.1007","volume":"82","author":[{"given":"Stefan","family":"Vordenb\u00e4umen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"1293_CR1","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.3390\/jcm10194544","volume":"10","author":"C Borciuch","year":"2021","unstructured":"Borciuch\u00a0C, Fauvernier\u00a0M, Gerfaud-Valentin\u00a0M et al (2021) Still\u2019s disease mortality trends in France, 1979\u20132016: a multiple-cause-of-death study. J\u00a0Clin Med 10:4544. https:\/\/doi.org\/10.3390\/jcm10194544","journal-title":"J Clin Med"},{"key":"1293_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","volume":"61","author":"Y Jamilloux","year":"2015","unstructured":"Jamilloux\u00a0Y, Gerfaud-Valentin\u00a0M, Martinon\u00a0F et al (2015) Pathogenesis of adult-onset Still\u2019s disease: new insights from the juvenile counterpart. Immunol Res 61:53\u201362. https:\/\/doi.org\/10.1007\/s12026-014-8561-9","journal-title":"Immunol Res"},{"key":"1293_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac027","author":"P Ruscitti","year":"2022","unstructured":"Ruscitti\u00a0P, Natoli\u00a0V, Consolaro\u00a0A et al (2022) Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Baillieres Clin Rheumatol. https:\/\/doi.org\/10.1093\/rheumatology\/keac027","journal-title":"Baillieres Clin Rheumatol"},{"key":"1293_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00393-020-00779-2","volume":"79","author":"D F\u00f6ll","year":"2020","unstructured":"F\u00f6ll\u00a0D, Wittkowski\u00a0H, Hinze\u00a0C (2020) Das Still-Syndrom als biphasische Erkrankung: Aktuelle Erkenntnisse zur Pathogenese und neue therapeutische Ans\u00e4tze. Z\u00a0Rheumatol 79:639\u2013648. https:\/\/doi.org\/10.1007\/s00393-020-00779-2","journal-title":"Z Rheumatol"},{"key":"1293_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00393-017-0358-5","volume":"76","author":"CM Hedrich","year":"2017","unstructured":"Hedrich\u00a0CM, G\u00fcnther\u00a0C, Aringer\u00a0M (2017) Morbus Still im Kindes- und Erwachsenenalter. Z\u00a0Rheumatol 76:595\u2013608. https:\/\/doi.org\/10.1007\/s00393-017-0358-5","journal-title":"Z Rheumatol"},{"key":"1293_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","volume":"70","author":"J Pouchot","year":"1991","unstructured":"Pouchot\u00a0J, Sampalis\u00a0JS, Beaudet\u00a0F et\u00a0al (1991) Adult Still\u2019s disease: manifestations, disease course, and outcome in 62\u00a0patients. Medicine 70:118\u2013136","journal-title":"Medicine"},{"key":"1293_CR7","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e\u00a0P, Horne\u00a0A, Hines\u00a0M et\u00a0al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133:2465\u20132477. https:\/\/doi.org\/10.1182\/blood.2018894618","journal-title":"Blood"},{"key":"1293_CR8","doi-asserted-by":"publisher","first-page":"102541","DOI":"10.1016\/j.jaut.2020.102541","volume":"116","author":"Q Bodard","year":"2020","unstructured":"Bodard\u00a0Q, Langlois\u00a0V, Guilpain\u00a0P et al (2020) Cardiac involvement in adult-onset Still\u2019s disease: manifestations, treatments and outcomes in a\u00a0retrospective study of 28\u00a0patients. J\u00a0Autoimmun 116:102541. https:\/\/doi.org\/10.1016\/j.jaut.2020.102541","journal-title":"patients. J\u00a0Autoimmun"},{"key":"1293_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13075-020-02245-5","volume":"22","author":"P Ruscitti","year":"2020","unstructured":"Ruscitti\u00a0P, Berardicurti\u00a0O, Iacono\u00a0D et al (2020) Parenchymal lung disease in adult onset Still\u2019s disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. Arthritis Res Ther 22:151. https:\/\/doi.org\/10.1186\/s13075-020-02245-5","journal-title":"Arthritis Res Ther"},{"key":"1293_CR10","first-page":"245","volume":"18","author":"JH Jung","year":"2000","unstructured":"Jung\u00a0JH, Jun\u00a0JB, Yoo\u00a0DH et al (2000) High toxicity of sulfasalazine in adult-onset Still\u2019s disease. Clin Exp Rheumatol 18:245\u2013248","journal-title":"Clin Exp Rheumatol"},{"key":"1293_CR11","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","volume":"39","author":"D Nordstr\u00f6m","year":"2012","unstructured":"Nordstr\u00f6m\u00a0D, Knight\u00a0A, Luukkainen\u00a0R et al (2012) Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study. J\u00a0Rheumatol 39:2008\u20132011","journal-title":"J Rheumatol"},{"key":"1293_CR12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","volume":"79","author":"C Kedor","year":"2020","unstructured":"Kedor\u00a0C, Listing\u00a0J, Zernicke\u00a0J et al (2020) Canakinumab for treatment of adult-onset still\u2019s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 79:1090\u20131097","journal-title":"Ann Rheum Dis"},{"key":"1293_CR13","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","volume":"77","author":"Y Kaneko","year":"2018","unstructured":"Kaneko\u00a0Y, Kameda\u00a0H, Ikeda\u00a0K et al (2018) Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: a\u00a0randomised, double-blind, placebo-controlled phase\u00a0III trial. Ann Rheum Dis 77:1720\u20131729. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213920","journal-title":"Ann Rheum Dis"},{"key":"1293_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13054-018-2012-2","volume":"22","author":"A N\u00e9el","year":"2018","unstructured":"N\u00e9el\u00a0A, Wahbi\u00a0A, Tessoulin\u00a0B et al (2018) Diagnostic and management of life-threatening adult-onset still disease: a\u00a0French nationwide multicenter study and systematic literature review. Crit Care 22:88. https:\/\/doi.org\/10.1186\/s13054-018-2012-2","journal-title":"Crit Care"},{"key":"1293_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fmed.2020.00042","volume":"7","author":"A Vitale","year":"2020","unstructured":"Vitale\u00a0A, Cavalli\u00a0G, Ruscitti\u00a0P et\u00a0al (2020) Comparison of early vs. Delayed Anakinra treatment in patients with adult onset still\u2019s disease and effect on clinical and laboratory outcomes. Front Med 7:42","journal-title":"Front Med"},{"key":"1293_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OARRR.S6696","volume":"3","author":"P Quartier","year":"2011","unstructured":"Quartier\u00a0P (2011) Interleukin\u20111 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome. Open Access Rheumatol 3:9\u201318","journal-title":"Open Access Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01293-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01293-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01293-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T13:06:49Z","timestamp":1677762409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01293-3"}},"subtitle":["Diagnostik und Therapie unter Ber\u00fccksichtigung der neuen DGRh(Deutsche Gesellschaft f\u00fcr Rheumatologie)-S2e-Leitlinie"],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1293"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01293-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"assertion":[{"value":"2 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>S.\u00a0Vordenb\u00e4umen<\/b>: A.\u00a0Finanzielle Interessen: gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Berufliche T\u00e4tigkeiten: angestellt als Chefarzt am St.\u00a0Elisabeth-Krankenhaus Meerbusch-Lank (St.\u00a0Franziskus-Stiftung M\u00fcnster); angestellt als wissenschaftlicher Mitarbeiter Poliklinik, Funktionsbereich & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Rheumatologie, Deutsche Gesellschaft f\u00fcr Nephrologie, Deutsche Gesellschaft f\u00fcr Immunologie, Rheumazentrum Rhein-Ruhr.<b> E.\u00a0Feist<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Novartis, Roche\/Chugai.\u00a0\u2013 Honorar als Referent: Novartis, Sobi, Roche\/Chugai, Medac. \u2013\u00a0Honorar als Berater von Novartis.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Chefarzt bei Helios Fachklinik f\u00fcr Rheumatologie; Vorstandsmitglied des BDRh.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}